['diabetes mellitus, type 1']
['ly900014', 'insulin lispro (humalog)']

        Inclusion Criteria:

          -  Male or female participants with Type 1 Diabetes Mellitus (T1DM) who are receiving
             insulin therapy via an approved insulin pump

          -  Have a screening body mass index (BMI) of greater than 18.5 to 33.0 kilograms per
             meter squared (kg/m²), inclusive

          -  Have medical and laboratory test results that are acceptable for the study

          -  Have had no episodes of severe hypoglycemia (requiring assistance in treatment by a
             second party) in the past 6 months

          -  Have venous access sufficient to allow for blood sampling

          -  Have provided written consent and are willing to follow study procedures and commit to
             the study duration

        Exclusion Criteria:

          -  Are currently participating or recently participated in a clinical trial or any other
             type of medical research judged to be incompatible with this study

          -  Had blood loss of more than 500 milliliters (mL) within the last month

          -  Have known allergies to LY900014, insulin lispro, related compounds or any components
             in the study drug formulations

          -  Have previously participated or withdrawn from this study

          -  Have or used to have health problems or medical test results that, in the opinion of
             the doctor, could make it unsafe to participate, or could interfere with understanding
             the results of the study
      